Sitemap
Glycotest
slider1 Slider2

Welcome to Glycotest

Glycotest Diagnostics is developing unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for people at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease.

Latest News

22-06-2016
Latest Investor Presentation
22-06-2016
Dr. Timothy Block, President, Baruch S. Blumberg Institute and the Hepatitis B Foundation, in a video on the Glycotest Technology
22-06-2016
Lawrence Cohen, CEO of Glycotest, presented at Net Scientific’s June 2016 Capital Markets Day.
08-06-2016
Lawrence Cohen, CEO of Glycotest, will be presenting the company at the New York Venture Summit on July 21, 2016.
06-01-2016
NetScientific portfolio company, Glycotest Inc., appoints world leading medical advisory board chaired by David Chernoff, M.D.
16-12-2015
NetScientific appoints diagnostics leader Lawrence Cohen as CEO of Glycotest Inc.
03-10-2014
NetScientific’s subsidiary, Glycotest Begins a New Research Collaboration with Oncimmune

Key Features

bollet
Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals
bollet
Incorporated into highly promising biomarker panels
bollet
Focused on the detection of potentially curable early-stage disease
bollet
May outperform currently available serum biomarkers, such as AFP
bollet
Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US